Last updated: September 8, 2026
Dulaglutide, marketed by Eli Lilly as Trulicity, remains one of the largest diabetes products globally, but its commercial trajectory has turned downward. Revenue peaked at $7.44 billion in 2022 and declined to $5.35 billion in 2024 as patients and prescribing volume shifted toward Lilly’s tirzepatide products, Mounjaro and Zepbound. Trulicity retains a large installed base, weekly dosing, cardiovascular-outcomes data, and broad diabetes labeling, but its growth prospects are limited by newer incretin therapies and eventual biosimilar competition.
How much revenue does dulaglutide generate?
Trulicity generated $5.35 billion in 2024, down from $7.13 billion in 2023 and $7.44 billion in 2022. The decline reflects competitive substitution and Lilly’s deliberate commercial transition toward higher-growth tirzepatide products.
| Fiscal year |
Trulicity revenue |
Year-over-year change |
| 2019 |
$3.21 billion |
33.4% |
| 2020 |
$5.07 billion |
58.0% |
| 2021 |
$6.47 billion |
27.8% |
| 2022 |
$7.44 billion |
15.0% |
| 2023 |
$7.13 billion |
-4.2% |
| 2024 |
$5.35 billion |
-24.9% |
Source: Eli Lilly annual reports and Form 10-K filings.[1-6]
From 2019 through 2022, Trulicity revenue expanded at approximately 32% annually. The product then entered a contraction phase. Revenue in 2024 was approximately 28% below the 2022 peak, although it remained materially larger than pre-2020 sales.
Trulicity’s 2024 revenue represented roughly 12% of Eli Lilly’s total revenue. The product remains financially important, but it is no longer one of the company’s primary growth engines.
Why is dulaglutide revenue declining?
The principal driver is internal and external competition from more potent incretin therapies.
Mounjaro, Lilly’s tirzepatide product for type 2 diabetes, combines glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonism. Zepbound is the same active ingredient approved for chronic weight management and obstructive sleep apnea in eligible patients. Both products have redirected physician attention, patient demand, manufacturing capacity, and Lilly’s promotional resources away from Trulicity.
The competitive pressure is reinforced by Novo Nordisk’s Ozempic and Rybelsus products for type 2 diabetes and Wegovy for obesity. Semaglutide has benefited from strong weight-loss efficacy, extensive consumer awareness, and broad use across diabetes and obesity markets.
Trulicity has several commercial disadvantages:
- It is a GLP-1 receptor agonist rather than a dual GIP/GLP-1 agonist.
- Its efficacy and weight-loss profile generally trails tirzepatide.
- It competes in a treatment class where patients and prescribers increasingly prioritize weight reduction.
- Lilly’s promotional and manufacturing priorities favor Mounjaro and Zepbound.
- Newer therapies have expanded the addressable obesity market beyond the traditional diabetes market.
Trulicity also benefits from a mature reimbursement position and physician familiarity. That support reduces the speed of decline but does not eliminate substitution risk.
What is the market position of Trulicity versus Mounjaro, Ozempic, and Wegovy?
Trulicity remains a diabetes-focused product. Its principal commercial strength is breadth within type 2 diabetes rather than leadership in obesity treatment.
| Product |
Active ingredient |
Company |
Primary commercial position |
Competitive effect on Trulicity |
| Trulicity |
Dulaglutide |
Eli Lilly |
Weekly GLP-1 for type 2 diabetes |
Baseline comparator and mature franchise |
| Mounjaro |
Tirzepatide |
Eli Lilly |
Weekly dual GIP/GLP-1 for type 2 diabetes |
Strongest internal substitution risk |
| Zepbound |
Tirzepatide |
Eli Lilly |
Obesity and related conditions |
Redirects Lilly growth and capacity |
| Ozempic |
Semaglutide |
Novo Nordisk |
Weekly GLP-1 for type 2 diabetes |
Direct class competitor |
| Wegovy |
Semaglutide |
Novo Nordisk |
Chronic weight management |
Expands demand for higher-efficacy incretins |
| Rybelsus |
Oral semaglutide |
Novo Nordisk |
Oral GLP-1 for type 2 diabetes |
Competes on administration convenience |
The cardiovascular-outcomes profile remains a relative strength. In the REWIND trial, dulaglutide reduced major adverse cardiovascular events in patients with type 2 diabetes, including many patients without established cardiovascular disease.[7] This evidence supports continued use in guideline-driven diabetes treatment, especially where cardiovascular risk reduction is important.
That advantage is increasingly shared by competing GLP-1 products. It is less differentiated than it was when Trulicity first established a broad cardiovascular-outcomes position.
What FDA approvals and regulatory protections apply to dulaglutide?
The FDA approved Trulicity in September 2014 for adults with type 2 diabetes as an adjunct to diet and exercise.[8] The product is a recombinant fusion protein containing dulaglutide, a modified GLP-1 analog linked to a human immunoglobulin G4 Fc fragment.
Key regulatory milestones include:
| Milestone |
Date |
| Original FDA approval |
September 2014 |
| Cardiovascular outcomes evidence from REWIND |
2019 |
| Pediatric type 2 diabetes approval for patients aged 10 and older |
2022 |
| Current regulatory category |
Biologic under the Public Health Service Act |
Dulaglutide is regulated as a biologic, not as a conventional small-molecule drug. It is therefore listed in the FDA Purple Book rather than handled through the standard Orange Book generic-substitution framework.[9]
The pediatric indication expanded the labeled population and may support pediatric-exclusivity benefits where FDA requirements were satisfied. The commercial effect is limited compared with the impact of adult diabetes and obesity prescribing.
When does dulaglutide lose regulatory exclusivity?
Dulaglutide received FDA approval on September 18, 2014. The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity for an approved biologic, subject to the statutory framework and any applicable pediatric extension.[10]
On that basis, the principal reference-product exclusivity period runs to September 2026. A qualifying six-month pediatric extension would move the date into March 2027.
Regulatory exclusivity does not determine the first possible biosimilar launch by itself. Patent rights, the biosimilar application process, litigation, settlement terms, and commercial launch decisions also affect market entry.
What patents protect dulaglutide?
Dulaglutide is protected by a layered patent estate covering the molecule, GLP-1 analog structure, fusion-protein architecture, formulations, manufacturing processes, and therapeutic uses. Publicly reported patent analyses generally place the most commercially relevant U.S. protection in the 2027 period, with some later-expiring secondary rights potentially affecting specific formulations or manufacturing methods.
The principal protection categories are:
Composition and molecule patents
These patents cover the dulaglutide fusion protein and related GLP-1 analog constructs. Composition claims are generally the most important barrier to an interchangeable or substitutable biosimilar launch because they can reach the active biologic itself.
Formulation patents
Formulation claims can cover concentration, stabilizers, buffers, storage conditions, and delivery characteristics. Trulicity is supplied in single-dose prefilled pens and single-dose syringes. Device and formulation rights can complicate a biosimilar launch even where a challenger avoids direct infringement of a core composition claim.
Method-of-use patents
Method claims may cover administration of dulaglutide for type 2 diabetes, glycemic control, cardiovascular-risk reduction, or particular patient populations. Their value depends on claim scope, enforceability, labeling, and whether a biosimilar sponsor can use a carve-out strategy.
Manufacturing patents
Manufacturing rights can cover recombinant expression, purification, aggregation control, and production of the fusion protein. These patents may raise development costs and create process-development risk, although they do not necessarily block a biosimilar using a noninfringing process.
Because the FDA Purple Book does not provide the same consolidated patent-listing mechanism used for small molecules in the Orange Book, public patent assessments for Trulicity require review of Lilly patent families, prosecution histories, terminal disclaimers, continuations, and litigation records.
Are there Paragraph IV challenges to dulaglutide?
Paragraph IV certifications apply to abbreviated new drug applications for small-molecule drugs under the Hatch-Waxman framework. Dulaglutide is a biologic, so a conventional Paragraph IV generic challenge is not the applicable pathway.
A prospective challenger would generally pursue a biosimilar application under section 351(k) of the Public Health Service Act. The process can include the BPCIA patent-information exchange, often called the patent dance, followed by patent litigation under 35 U.S.C. § 271(e)(6).
No conventional generic version of dulaglutide can rely on an ANDA pathway. Any future competitive product would need to qualify as a biosimilar or pursue a separate biologic approval route.
Which companies are challenging Trulicity exclusivity?
The main future challengers are expected to be biosimilar developers with experience in complex biologics, injectable diabetes products, or large-scale recombinant manufacturing. Publicly visible commercial competition has so far been more significant than disclosed litigation against Trulicity’s core patent estate.
Potential challenger categories include:
- Large generic and biosimilar companies such as Sandoz, Biocon Biologics, Viatris, Samsung Bioepis, and Celltrion.
- Contract development and manufacturing organizations with recombinant-protein capabilities.
- Diabetes-focused companies seeking lower-cost GLP-1 products.
- Regional manufacturers targeting markets where patent and regulatory barriers expire earlier.
The absence of a major disclosed biosimilar launch does not eliminate future risk. Dulaglutide’s revenue base makes it attractive, but the expected return depends on development cost, clinical comparability requirements, manufacturing scale, payer discounts, and the remaining life of Lilly’s patent estate.
What is the likely generic or biosimilar launch scenario?
The most probable launch sequence is a gradual biosimilar erosion rather than an immediate small-molecule-style price collapse.
A biosimilar entrant would face several barriers:
- Analytical and clinical comparability requirements for a complex fusion protein.
- Manufacturing scale and batch-consistency requirements.
- Device compatibility for the single-dose pen or an alternative delivery system.
- Patent litigation over composition, formulation, use, and manufacturing claims.
- Payer contracting against established GLP-1 products.
- A market increasingly dominated by tirzepatide and semaglutide.
If the first biosimilar enters near the end of the decade, the product may encounter a shrinking branded market. That could reduce the value of the opportunity while increasing pressure for aggressive pricing.
A plausible erosion pattern is:
| Period |
Commercial expectation |
| 2025-2026 |
Continued branded decline driven by Mounjaro, Zepbound, Ozempic, and Wegovy |
| 2026-2027 |
Reference-product exclusivity expiration window |
| 2027 onward |
Greater probability of biosimilar filings, patent settlements, or launch preparations |
| Post-entry |
Price erosion moderated by biologic substitution rules and payer contracting |
How strong is the dulaglutide patent estate?
The estate is commercially meaningful but increasingly time-limited.
Its strongest features are the biologic composition claims, the complexity of the fusion protein, and the operational difficulty of reproducing a weekly injectable product at commercial scale. Its weaker features are the approaching end of reference-product exclusivity, the mature clinical profile of the molecule, and the availability of competing mechanisms with stronger weight-loss positioning.
Patent strength should be assessed claim by claim. A broad composition claim can support a substantial barrier. Narrow formulation or manufacturing claims may delay a particular product configuration without preventing a biosimilar using a different process or presentation.
The absence of Orange Book-style listing certainty also makes freedom-to-operate analysis more dependent on the full patent family and prosecution record.
What licensing deals affect dulaglutide?
Dulaglutide was developed and commercialized by Eli Lilly. No major third-party licensing transaction has been publicly identified as a principal driver of Trulicity’s economics. Lilly controls the core commercial franchise, manufacturing strategy, regulatory filings, and principal intellectual-property position.
That differs from some biologic franchises built through external licensing or co-development. For Trulicity, value concentration is primarily within Lilly rather than split among multiple originator partners.
What is the revenue exposure for Eli Lilly?
Trulicity is becoming a declining but still material cash-flow asset.
At $5.35 billion in 2024 revenue, a 10% decline in Trulicity sales would reduce Lilly’s annual revenue by approximately $535 million before offsetting factors. A 25% decline would imply approximately $1.34 billion in lost annual revenue.
The financial risk is partly mitigated by Lilly’s product mix. Mounjaro and Zepbound are growing faster and have substantially improved the company’s exposure to the broader obesity and metabolic-disease market. As a result, Trulicity erosion represents a portfolio transition rather than a standalone threat to Lilly’s overall growth model.
The principal financial variables are:
- The pace of switching from Trulicity to tirzepatide.
- Supply availability for Mounjaro and Zepbound.
- Reimbursement and prior-authorization policies.
- Net price after rebates and discounts.
- The timing of biosimilar entry.
- The strength of Trulicity’s cardiovascular and primary-care positioning.
Key Takeaways
- Trulicity revenue peaked at $7.44 billion in 2022 and fell to $5.35 billion in 2024.
- The main cause of decline is competition from Mounjaro, Zepbound, Ozempic, and Wegovy.
- Dulaglutide is a biologic and does not face conventional Paragraph IV generic challenges.
- Reference-product exclusivity runs to September 2026, with a possible pediatric extension into 2027.
- Core patent protection is generally reported through approximately 2027, while secondary rights may extend beyond that period.
- Future competition will come through the 351(k) biosimilar pathway.
- Trulicity remains protected by cardiovascular-outcomes data, weekly dosing, physician familiarity, and a mature reimbursement base.
- Lilly’s growing tirzepatide franchise reduces the strategic impact of Trulicity’s decline.
Frequently Asked Questions
Is dulaglutide still commercially important to Eli Lilly?
Yes. Trulicity generated $5.35 billion in 2024, but its importance is declining as Mounjaro and Zepbound become Lilly’s principal incretin growth products.
Is Trulicity an interchangeable biosimilar?
No. Trulicity is the reference biologic. An interchangeable biosimilar would require a separate FDA approval and a finding that satisfies the interchangeability standard.
Can a generic manufacturer file an ANDA for dulaglutide?
No. Dulaglutide is a biologic. A competing manufacturer would generally use the 351(k) biosimilar pathway rather than an ANDA and Paragraph IV certification.
Does dulaglutide have an obesity indication?
No. Trulicity is approved for type 2 diabetes, not chronic weight management. This limits its direct participation in the rapidly expanding obesity-drug market.
What is the largest long-term risk to Trulicity revenue?
The largest risk is therapeutic substitution by tirzepatide and semaglutide, not immediate biosimilar entry. These products compete on glucose control, weight loss, cardiovascular outcomes, and market visibility.
References
- Eli Lilly and Company. (2020). 2020 annual report.
- Eli Lilly and Company. (2021). 2021 annual report.
- Eli Lilly and Company. (2022). 2022 annual report.
- Eli Lilly and Company. (2023). 2023 annual report.
- Eli Lilly and Company. (2024). 2024 annual report.
- Eli Lilly and Company. (2025). Form 10-K for the fiscal year ended December 31, 2024.
- Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes. The Lancet, 394(10193), 121-130.
- U.S. Food and Drug Administration. (2014). Trulicity prescribing information.
- U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products.
- Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
